OTCMKTS:RGIN Regenicin (RGIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Regenicin Stock (OTCMKTS:RGIN) 30 days 90 days 365 days Advanced Chart Get Regenicin alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume17,300 shsMarket Capitalization$17 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRegenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.Read More… Receive RGIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regenicin and its competitors with MarketBeat's FREE daily newsletter. Email Address RGIN Stock News HeadlinesHistoryOctober 20, 2024 | npr.orgRegenicin, Inc. (RGIN)September 5, 2024 | finance.yahoo.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.June 14, 2025 | Brownstone Research (Ad)LGBT+ History Month - Teaching ResourcesMay 3, 2024 | bbc.co.ukJohn Kerry praises Biden for preventing 'uncontrolled war in many regions'January 20, 2024 | foxnews.comHistory of Walmart: Timeline and FactsDecember 9, 2023 | thestreet.comHeavy rains trigger floods and landslides in India's Himalayan region, leaving at least 48 deadAugust 22, 2023 | foxnews.comUkraine army attacks Russian forces in southern Zaporizhzhia regionJune 13, 2023 | bbc.comSee More Headlines RGIN Stock Analysis - Frequently Asked Questions How were Regenicin's earnings last quarter? Regenicin, Inc. (OTCMKTS:RGIN) posted its earnings results on Wednesday, August, 19th. The company reported $0.00 earnings per share for the quarter. How do I buy shares of Regenicin? Shares of RGIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regenicin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regenicin investors own include Energous (WATT), Cheniere Energy (LNG), Vital Therapies (VTL), Xerox (XRX), Allergan (AGN) and Leafbuyer Technologies (LBUY). Company Calendar Last Earnings8/19/2020Today6/14/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:RGIN CIK1412659 Webwww.regenicin.com Phone(732) 757-5500FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares165,770,000Free FloatN/AMarket Cap$17 thousand OptionableNot Optionable Beta-18.91 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (OTCMKTS:RGIN) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regenicin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regenicin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.